GSK, a British drugmaker, has made a significant move in the oncology sector with its record $10.6 billion deal to acquire U.S. company Nuvalent. This acquisition is expected to accelerate GSK’s rebuild of its cancer drug business, allowing it to better compete with larger rivals such as AstraZeneca and Roche.
Oncology Expansion
The takeover, codenamed Nashville, brings two lung cancer treatments that could be approved in the U.S. this year, adding to GSK’s portfolio and helping to offset the impact of patent cliffs later this decade. The deal is part of CEO Luke Miels’ plan to expand the company’s presence in oncology, a business it left a decade ago.
GSK’s strategy has been a brick-by-brick building approach, with the Nuvalent deal being a significant step in this process. The company had previously made smaller moves into oncology, including a $5.1 billion deal for Tesaro in 2018 and a nearly $2 billion purchase of Sierra Oncology.
Market Impact
The acquisition is expected to help GSK achieve its £40 billion sales target by 2031. The Nuvalent deal brings de-risked products that together should be able to achieve $3 billion to $4 billion peak sales, helping counter the loss of exclusivity for HIV treatments.
Analysts have noted that while the acquisition makes sense, neither asset appears to have ‘mega blockbuster’ status. However, GSK expects that small patient groups could become sizeable opportunities if the therapies keep younger, active patients on treatment for years with fewer side effects than existing medicines.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
